Patients Experienced Pseudoprogression to Anti-PD1/PD-L1 Inhibitor Have Better Response Than Those Without in Lung Cancer

被引：0
|
作者：
Zhao, W. [1 ,2 ]
Zhou, F. [1 ,2 ]
Li, W. [2 ,3 ]
Qian, D. [1 ,2 ]
Zhang, J. [1 ,2 ]
Wu, F. [1 ,2 ]
Zhou, C. [1 ,2 ]
机构：
[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Pseudoprogression; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.10
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [41] Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes
    Vokes, N.
    Jimenez Alguilar, E.
    Adeni, A.
    Umeton, R.
    Sholl, L.
    Rizvi, H.
    Hellmann, M.
    Awad, M.
    Van Allen, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S422 - S422
  • [42] PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
    Gandini, Sara
    Massi, Daniela
    Mandala, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 88 - 98
  • [43] Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC
    Cerniglia, Michael
    Klepadlo, Michal
    Sheneman, David
    Kim, Sunnie S.
    BMJ CASE REPORTS, 2022, 15 (08)
  • [44] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [45] Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies
    Nagai, Yoshiaki
    Sata, Masafumi
    Ohta, Hiromitsu
    Onuki, Tsugitoshi
    Saito, Tatsuya
    Uchiyama, Ayumi
    Kurosaki, Ayako
    Yoshizumi, Naoko
    Takigami, Ayako
    Nakazawa, Shoko
    Nakayama, Masayuki
    Yamaguchi, Hironori
    Hagiwara, Koichi
    IMMUNOTHERAPY, 2022, 14 (15) : 1211 - 1217
  • [46] Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients
    Li, Janice J. N.
    Karim, Khizar
    Sung, Mike
    Le, Lisa W.
    Lau, Sally C. M.
    Sacher, Adrian
    Leighl, Natasha B.
    LUNG CANCER, 2020, 150 : 159 - 163
  • [47] A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
    Puyalto, Ander
    Rodriguez-Remirez, Maria
    Lopez, Ines
    Iribarren, Fabiola
    Simon, Jon Ander
    Ecay, Marga
    Collantes, Maria
    Vilalta-Lacarra, Anna
    Francisco-Cruz, Alejandro
    Solorzano, Jose Luis
    Sandiego, Sergio
    Penuelas, Ivan
    Calvo, Alfonso
    Ajona, Daniel
    Gil-Bazo, Ignacio
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] PD-L1 Expression in Circulating Tumor Cells and Response to PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer Patients
    Guibert, N.
    Delaunay, M.
    Boubekeur, N.
    Rouquette, I.
    Lusque, A.
    Clermont, E.
    Fortoul, A.
    Farella, M.
    Favre, G.
    Pradines, A.
    Mazieres, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1997 - S1997
  • [49] PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas
    Perottet, Jeremy
    Le Goff, Emeline
    Legoupil, Delphine
    Quere, Gilles
    Schick, Ulrike
    Marcorelles, Pascale
    Uguen, Arnaud
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (02) : 161 - 165
  • [50] PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy
    Goldmann, T.
    Kugler, C.
    Reinmuth, N.
    Vollmer, E.
    Reck, M.
    ANNALS OF ONCOLOGY, 2016, 27 (01) : 206 - 207
12345